Active	Status	Sponsor type	Region	Phase	Filter
3 Active 0 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
LY3866288 / Eli Lilly
NCT06641037: A Study of LY3866288 in Healthy Participants	Recruiting	1	30	US	LY3866288	Eli Lilly and Company	Healthy	02/25	02/25
NCT06644378: A Study of [14C]-LY3866288 in Healthy Participants	Recruiting	1	16	US	[14C]-LY3866288, LY3866288	Eli Lilly and Company	Healthy	01/25	01/25
FORAGER-1, NCT05614739: A Study of LOXO-435 in Participants With Cancer With a Change in a Gene Called FGFR3	Recruiting	1	180	Europe, Canada, Japan, US, RoW	LOXO-435, LY3866288, Pembrolizumab, KEYTRUDA®	Eli Lilly and Company, Merck Sharp & Dohme LLC	Urinary Bladder Neoplasms, Neoplasm Metastasis, Ureteral Neoplasms	06/25	06/25